secwatch.observer — SEC 8-K summary
======================================

Issuer:     PLIANT THERAPEUTICS, INC. (PLRX)
CIK:        0001746473
Form:       8-K
Filed at:   2024-02-05T23:59:59+00:00
Accession:  0001193125-24-023459
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pliant reports positive Phase 2a data for bexotegrast 320 mg in PSC; fibrosis markers improved
--------------------------------------------------------------------------------

- Bexotegrast 320 mg well tolerated with no drug-related severe or serious adverse events; 96% of 27 patients completed 12 weeks.
- Reduced ELF and PRO-C3 levels relative to placebo at Week 12, indicating antifibrotic activity.
- Stabilized alkaline phosphatase and showed improved hepatocyte function and bile flow on contrast MRI vs placebo.
- Statistically significant reduction in itch Numerical Rating Scale at Week 12 for the 320 mg dose.
- Company plans to share data with regulatory authorities to discuss potential registration path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524023459/0001193125-24-023459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746473/000119312524023459/d734141d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-023459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer